Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 4
Opinion
Video
Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
Author(s):
Key Takeaways
- Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction.
- Patients with specific genetic mutations may benefit more from targeted therapies than chemotherapy.
The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations.
Video Player is loading.
Video Content above is prompted by the following:
- For which patients would you choose or avoid a combination that includes chemotherapy?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
Topline Data From the BOND-003 Trial in NMIBC
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Remaining unmet needs in diverse populations with mHSPC
Related Content
